Several subunits of the class III phosphatidylinositol-3-OH kinase (PI(3)K-III) complex are known as tumour suppressors. Here we uncover a function for this complex and its catalytic product phosphatidylinositol-3-phosphate (PtdIns(3)P) in cytokinesis. We show that PtdIns(3)P localizes to the midbody during cytokinesis and recruits a centrosomal protein, FYVE-CENT (ZFYVE26), and its binding partner TTC19, which in turn interacts with CHMP4B, an endosomal sorting complex required for transport (ESCRT)-III subunit implicated in the abscission step of cytokinesis. Translocation of FYVE-CENT and TTC19 from the centrosome to the midbody requires another FYVE-CENT-interacting protein, the microtubule motor KIF13A. Depletion of the VPS34 or Beclin 1 subunits of PI(3)K-III causes cytokinesis arrest and an increased number of binucleate and multinucleate cells, in a similar manner to the depletion of FYVE-CENT, KIF13A or TTC19. These results provide a mechanism for the translocation and docking of a cytokinesis regulatory machinery at the midbody.
, is defined by the constriction of the cytoplasm between the two re-forming nuclei through the assembly of an actomyosin contractile ring. This constriction results in the formation of a narrow intercellular bridge, the midbody, filled with central spindle microtubules 1, 2 . Completion of cytokinesis requires cleavage of the midbody in a process called abscission [2] [3] [4] . Failure to complete cytokinesis has been shown to promote aneuploidy and has been associated with tumorigenesis [5] [6] [7] . Recent studies have identified certain proteins that localize to centrosomes early in mitosis and later to the midbody and are required for the completion of abscission [8] [9] [10] [11] [12] . How centrosomal proteins move to the midbody and are retained there remains largely unknown.
One mechanism for anchoring cytosolic proteins to membranes is by virtue of their binding to phosphorylated derivatives of the membrane lipid phosphatidylinositol (PtdIns), known as phosphoinositides. These lipids regulate cytoskeletal functions, membrane trafficking and receptor signalling through the reversible recruitment of protein complexes to specific membranes [13] [14] [15] [16] . A well-studied example is PtdIns(3)P, which is enriched on endosomal membranes. The first known functions of PtdIns(3)P were in the regulation of vesicular trafficking in the endolysosomal system 17 . However, PtdIns(3)P has also been implicated in other signalling processes, including nutrient sensing, receptor signalling and autophagy 17, 18 . Even though endosomes have been implicated in cytokinesis 2, 3, 19, 20 , it is not known whether PtdIns(3)P and its effectors are involved in this process.
Here we investigate the possible function of PtdIns(3)P in cytokinesis. We demonstrate that PtdIns(3)P is required for proper cytokinesis and identify a PtdIns(3)P-binding protein, FYVE-CENT, and its interacting partners TTC19 and KIF13A as components of a machinery that regulates cytokinesis. We show that KIF13A-dependent recruitment of FYVE-CENT and TTC19 to the midbody controls cytokinesis.
RESulTS

PtdIns(3)P localizes to the midbody and is required for cytokinesis
To study the localization pattern of PtdIns(3)P during cytokinesis, we used a green fluorescent protein (GFP)-tagged tandem FYVE domain (GFP-2×FYVE), which is a widely used probe for monitoring PtdIns(3) P distribution 21 . HeLa cells transfected with the GFP-2×FYVE probe show a punctuate pattern of GFP-positive spots that mostly represent endosomes 21 . In cells undergoing early and late cytokinesis, the 2×FYVE probe, but not a point mutant defective in PtdIns(3)P binding, stained the Aurora B-positive 22 midbody ( Fig. 1a ; Supplementary Information, Fig. S1a-g ). PtdIns(3)P-containing vesicles were frequently observed close to the midbody ring, presumably in transit to the ring ( Fig. 1a , inset; Supplementary Information, Fig. S1a, b) . These vesicles were found to co-localize with the recycling endosomal marker transferrin ( Supplementary Information, Fig. S1g) .
To examine the possible requirement for PtdIns(3)P during cytokinesis, small interfering RNA (siRNA) was used to knock down the class II and III phosphatidylinositol-3-OH kinases (PI(3)K-II and PI(3)K-III) known to mediate its formation 16 . Depletion of one of these, the PI(3)K-III VPS34, did indeed cause an increased number of cells in cytokinesis and also led to increased numbers of binucleate and multinucleate cells. The same was true when an accessory subunit of the PI(3)K-III complex, the tumour suppressor Beclin 1, was Supplementary Information, Fig. S4 ). Consistent with a role for PI(3)K-III in cytokinesis was our observation that endogenous VPS34 localized to the midbody (Fig. 1e) . To test the importance of VPS34 for cell division in vivo, we studied clones of vps34 mutant cells in the follicular epithelium of the Drosophila egg chamber. This analysis showed that cells mutant for vps34 showed a fivefold increase in the binucleate phenotype compared with the wildtype neighbouring cells (Fig. 1f) . Taken together, these data demonstrate that PtdIns(3)P is localized to the midbody during cytokinesis and is required for its normal completion in cell culture and in a multicellular model organism.
FYVE-CENT, a PtdIns(3)P-binding protein, localizes to the centrosome and midbody
To identify possible effectors of PtdIns(3)P in cytokinesis, HeLa cells were screened with a siRNA library targeting proteins with known PtdIns(3)P-binding domains, the FYVE and PX domains 23 (Fig. 2) . The strongest positive hit with this strategy was ZFYVE26, a roughly 285-kDa FYVE domain protein whose depletion caused the highest proportion of cells arrested in cytokinesis (see below and Fig. 2) . To study the expression and intracellular localization of ZFYVE26, a rabbit antiserum was raised against two specific peptides located in its amino-terminal and carboxy-terminal parts, respectively. Fluorescence microscopy with anti-ZFYVE26 showed that the major localization of this protein was on one or two punctate structures in each cell, and co-localization with the centrosomal marker γ-tubulin revealed that ZFYVE26 localizes on the centrosome (Fig. 3a) . We therefore named the protein product of the ZFYVE26 gene FYVE-CENT (FYVE-domaincontaining centrosomal protein).
To establish the localization of FYVE-CENT during the cell cycle we examined the subcellular localization of FYVE-CENT in HeLa cells that were synchronized and fixed in G1, S or M phase. This analysis showed that FYVE-CENT is localized to the centrosome at all stages of the cell cycle (Fig. 3a-e) . The protein also localized to the midbody during cytokinesis (Fig. 3e, f; Supplementary Information,  Fig. S5a ). Immunoelectron microscopy of cells in G1 phase revealed the presence of FYVE-CENT on the centrioles (Fig. 3g) . FYVE-CENT did not co-localize with various endosomal (EEA1, CD63 or endocytosed transferrin) or autophagic (GFP-LC3) markers ( Supplementary  Information, Fig. S5d-g ). A previous study reported localization of the overexpressed ZFYVE26 gene product to early endosomes in COS-7 cells 24 . However, in our hands, overexpressed FYVE-CENT localized to the centrosome in HeLa cells (not shown), which is consistent with the localization of endogenous FYVE-CENT. Deletion mutagenesis showed that the C-terminal part of FYVE-CENT was sufficient for localization to the centrosome and midbody. However, the N-terminal part also showed a weak localization to the centrosome ( Supplementary Information, Fig. S6 and Table S1 ). These results suggest that the subcellular targeting of FYVE-CENT is primarily mediated by its C terminus, and that the N terminus possibly also contributes by binding to centrosomal proteins.
FYVE-CENT is required for cytokinesis
Because the siRNA screen was performed with pools of four siRNAs, the screening result needed to be verified with deconvoluted single siRNAs. Both the siRNA pool and the individual siRNAs against FYVE-CENT caused a significant decrease in the 285-kDa FYVE-CENT-reactive band compared with cells treated with control RNA duplex ( Fig. 4a ; Supplementary  Information, Fig. S7c ). To ascertain whether knockdown of FYVE-CENT with single siRNAs affects cytokinesis, HeLa cells were transfected with FYVE-CENT siRNAs and observed by confocal fluorescence microscopy, using Aurora B as a marker for the midbody and Hoechst staining to reveal nuclei. Quantification of multiple micrographs showed that the percentages of binucleate and multinucleate cells and cells undergoing cytokinesis were markedly increased after FYVE-CENT knock-down even with single siRNAs (Fig. 4b, c ; Supplementary Information, Figs S2d, k and S3c, h). Back-transfection of the FYVE-CENT transgene reverted the phenotype ( Supplementary Information, Fig. S8b, d ). Together, these results indicate that FYVE-CENT, like PI(3)K-III, is required for proper cytokinesis.
A functional FYVE domain is important for targeting of FYVE-CENT to the midbody To examine whether the FYVE domain of FYVE-CENT binds to PtdIns(3)P, the recombinant FYVE domain was purified as a glutathione S-transferase (GST) fusion protein and incubated with liposomes containing various phosphoinositides (PtdIns(3)P, PtdIns(4,5)P 2 , PtdIns(3,5)P 2 and PtdIns(3,4,5)P 3 ). The GST-tagged FYVE domain of FYVE-CENT bound strongly only to PtdIns(3)P, as determined by western blotting with an anti-GST antibody. As expected, mutation of a conserved arginine residue (R1835A) in the FYVE domain predicted to bind directly to PtdIns(3)P (refs 25, 26), significantly decreased the ability to bind PtdIns(3)P (Fig. 5a ).
We conclude that the FYVE domain of FYVE-CENT, similarly to other FYVE domains tested, binds specifically to PtdIns(3)P. To study the importance of the FYVE domain in the subcellular targeting of FYVE-CENT, the R1835A mutant version of the C terminus of FYVE-CENT was next expressed in HeLa cells and its intracellular localization was determined. In contrast to the wild-type FYVE-CENT C terminus, which localized to the midbody during cytokinesis, the R1835A mutant did not localize to the midbody but had a cytosolic and nuclear distribution (Fig. 5b, c, e) . The same occurred with a construct in which the FYVE domain had been deleted (Fig. 5d, e) . In interphase cells the R1835A construct localized to the centrosome similarly to the wild-type C terminus ( Supplementary Information, Fig. S6g ). These findings indicate that the FYVE domain is critical for the targeting of FYVE-CENT to the midbody but not for targeting to the centrosome.
FYVE-CENT interacts with KIF13A and TTC19
FYVE-CENT is the first PtdIns(3)P-binding protein that has been shown to translocate from the centrosome to the midbody during cytokinesis; we next examined whether its interacting partners could shed light on its mechanisms of localization and function. To identify interacting partners for FYVE-CENT, we performed a yeast two-hybrid screen, using the C-terminal part of FYVE-CENT as bait. The two strongest hits in this screen were KIF13A and TTC19 ( Supplementary Information, Fig. S9 ). KIF13A is a plus-end-directed microtubule-dependent motor protein involved in mannose-6-phosphate receptor transport to the plasma membrane 27 . Its interaction with FYVE-CENT did not map to its canonical cargo-binding domain but was instead located to a region containing a forkhead-homology-associated (FHA) domain ( Supplementary Information, Fig. S10 ), a domain found in all members of the kinesin-3 family. TTC19, a previously uncharacterized protein, contains five tetratricopeptide repeats, first described as a protein-protein interaction domain in yeast cell cycle proteins 28 . To verify the interactions biochemically, cell lysates containing Myc-epitope-tagged KIF13A or TTC19 were incubated with beads containing the C terminus of FYVE-CENT fused to GST. This assay showed that Myc-KIF13A and Myc-TTC19 were pulled down by the C terminus of GST-FYVE-CENT by not by GST alone, thereby confirming the results from the two-hybrid screen ( Fig. 6a-c) . Finally, endogenous KIF13A and FYVE-CENT were co-immunoprecipitated with an antibody against endogenous TTC19 (Fig. 6d) , indicating that the three proteins can exist as a physical complex in vivo.
The interactions of FYVE-CENT with KIF13A and TTC19 raised the possibility that these proteins share the subcellular distribution of FYVE-CENT. Immunofluorescence microscopy showed that endogenous KIF13A co-localizes with γ-tubulin on the centrosome and with Aurora B on the midbody ( Fig. 7a ; Supplementary Information, Fig. S5c ). Overexpressed Myc-epitope-tagged KIF13A also co-localized with CEP55, a known marker for the midbody and the centrosome (Fig. 7a) . Similarly, endogenous TTC19 co-localized with γ-tubulin and Aurora B on the centrosome and the midbody ( Fig. 7b ; Supplementary Information, Fig. S5b ). TTC19 did not localize to the centrosomes during cytokinesis, suggesting that it translocates from the centrosome to the midbody during this phase of cell division (Fig. 7b) . siRNA-mediate depletion of KIF13A or TTC19 resulted in arrest in cytokinesis and in increased numbers of binuclear and multinuclear cells ( Fig. 7c- GFP-2×FYVE
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FYVE-CENT C-term ∆FYVE Back-transfection of the KIF13A and TTC19 transgenes rescued the phenotype ( Supplementary Information, Figs S8a, c and S11 ). Thus, similarly to their interacting partner FYVE-CENT, KIF13A and TTC19 are regulators of cytokinesis.
Having established a role for PI(3)K-III complex, FYVE-CENT, KIF13A and TTC19 in cytokinesis, we next sought to identify at which stage in cytokinesis these proteins come into action. For this purpose, each of these proteins was knocked down by siRNA, the cells KIF13A siRNA TTC19 siRNA
Figure 7
The FYVE-CENT-interacting proteins KIF13A and TTC19 localize to the centrosome and midbody and control cytokinesis. (a) Confocal micrographs of HeLa cells stained for KIF13A, FYVE-CENT, γ-tubulin and Aurora B. KIF13A localizes to the centrosome and to the midbody, co-localizing with FYVE-CENT, γ-tubulin and Aurora B (arrows). KIF13A localizes to centrosomes in 86.3 ± 1.8% s.d. of cells in interphase (n = 1,083) and in 90.1 ± 2.2% of cells in mitosis (n = 672). KIF13A localizes to the midbody during cytokinesis in 72.6 ± 1.8% of cells (n = 1,196). HeLa cells transfected with KIF13A-Myc were stained for CEP55. KIF13A co-localizes with CEP55 to the midbody (arrows, bottom panels) in 86.7 ± 1.8% of cells (n = 320). DNA was stained with Draq5 (blue). (b) Confocal micrographs of HeLa cells stained for TTC19 and γ-tubulin. TTC19 localizes to the centrosome and to the midbody, colocalizing with γ-tubulin (arrows) in G1, metaphase, anaphase and cytokinesis. TTC19 localizes to centrosomes in 78.3 ± 1.1% of cells in interphase (n = 1,390) and in 85.3 ± 2.4% of cells in mitosis (n = 771). TTC19 localizes to the midbody during cytokinesis in 91.6 ± 1.8% of cells (n = 1,003 experiments, n = 521 cells; KIF13A siRNA 1, three independent experiments, n = 1,182 cells; KIF13A siRNA 2, three independent experiments, n = 1,020 cells; KIF13A siRNA 3, two independent experiments, n = 402 cells. Right: control, three independent experiments, n = 732 cells; TTC19 siRNA 1, three independent experiments, n = 834 cells; TTC19 siRNA 2, three independent experiments, n = 890 cells. Scale bars, 5 µm. Uncropped images of blots are shown in Supplementary Information, Fig. S18 .
were stained for Aurora B, α-tubulin and DNA, and analyses of cell division profiles were recorded from a large number of cells with an automated fluorescence microscope. Using this strategy we observed that cells depleted of VPS34, FYVE-CENT and KIF13A were mainly arrested in early cytokinesis (defined by Aurora-B-positive midbodies and incompletely decondensed chromatin), although to some extent also in late cytokinesis (defined by Aurora-B-positive midbodies and fully decondensed nuclei). However, TTC19-depleted cells were mainly arrested in late cytokinesis, similarly to TSG101, which is thought to function in the final abscission step together with other components of the endosomal sorting complex required for transport (ESCRT) machinery 10, 11 ( Fig. 8a ; Supplementary Information, Figs S2 and S3). This suggests that TTC19 functions after PtdIns(3)P, FYVE-CENT and KIF13A in cytokinesis.
TTC19 interacts with the ESCRT-III subunit CHMP4B
TTC19 has previously been identified as a possible interacting partner of the ESCRT-III subunit CHMP4A in a yeast two-hybrid screen 29 , which is of interest because ESCRT-III components have been proposed to mediate midbody abscission through their interaction with centrosomal proteins and midbody membranes 10, 11, 12, 30, 31 . Because we found that endogenous CHMP4B, which is closely related to CHMP4A, localizes strongly to the midbody during cytokinesis ( Supplementary Information, Fig. S12a, b) , we examined whether TTC19 interacts with this protein. We found that TTC19 interacts with CHMP4B in a pull-down assay ( Supplementary  Information, Fig. S12c, d ) and that endogenous TTC19 could be coimmunoprecipitated with endogenous CHMP4B from a HeLa cell lysate ( Supplementary Information, Fig. S12e ). When cells were depleted of CHMP4B, the localization of TTC19 on the midbody was markedly decreased ( Supplementary Information, Fig. S12f-i ). This suggests that CHMP4B and TTC19 interact functionally at the midbody, and is consistent with the possibility that TTC19 could be a regulator of CHMP4B.
KIF13A-dependent translocation of FYVE-CENT and TTC19 to the midbody
Given the capability of KIF13A to translocate vesicles and cargo molecules towards the cell periphery, we speculated that this microtubule motor protein might mediate the localization of FYVE-CENT and TTC19 to the midbody. To test this idea, KIF13A in HeLa cells was knocked down with siRNA and the cells were stained for FYVE-CENT and TTC19. Depletion of KIF13A did indeed abolish FYVE-CENT and TTC19 localization from the midbody (Fig. 8b, c; Supplementary Information,  Fig. S13 ). Furthermore, depletion of FYVE-CENT also abolished the localization of TTC19 from the midbody (Fig. 8b, c) . Localization of FYVE-CENT and TTC19 to the midbody was significantly decreased when VPS34 and Beclin 1 were depleted, but midbody localization of KIF13A was not affected ( Supplementary Information, Figs 14-16 ). In contrast, TTC19 knockdown had no effect on FYVE-CENT or KIF13A localization to the midbody ( Supplementary Information, Fig. 17 ). Taken together, these data suggest that KIF13A transports FYVE-CENT and TTC19 to the midbody, where FYVE-CENT can dock to PtdIns(3)P and TTC19 to CHMP4B. It is possible that the specific docking at the midbody is mediated by a simultaneous detection of PtdIns(3)P and TTC19, although it is also possible that transport to the midbody is required for exposure of the FYVE domain of FYVE-CENT. On the basis of these data and the high-content microscopy described above, we propose that PtdIns(3)P controls the KIF13A-dependent recruitment of FYVE-CENT and TTC19 to the midbody, and that TTC19 is the most downstream effector of the three, possibly controlling the function of CHMP4B.
DISCuSSION
Our data demonstrate that PtdIns(3)P production is essential for proper cytokinesis and suggest that the PtdIns(3)P-binding centrosomal protein FYVE-CENT and its interacting protein TTC19 control cytokinesis through their translocation from the centrosome to the midbody mediated by the kinesin protein KIF13A. This model (Fig. 8d) explains the significant increase in cells arrested in cytokinesis and also binucleate and multinucleate cells when FYVE-CENT, TTC19 and KIF13A are depleted. Even though such depletions only affected a minor proportion of the cell population (a similar penetrance to that of depletion of the ESCRT protein TSG101), they are likely to reflect an important regulatory function of FYVE-CENT, TTC19 and KIF13A in cytokinesis. In terms of oncogenesis, the loss of protein functions that affect only a minor proportion of cells could well be more severe than the loss of more central factors, because the latter is more likely to cause cell death than tumourigenesis. Even though multiple proteins are known to mediate (or regulate) cytokinesis, the exact biochemistry of the abscission step remains unknown 4 . The recent identification of the ESCRT-III complex, a well-known machinery for inward membrane budding, in cytokinesis is conceptually interesting because it suggests a model for the final membrane abscission step [10] [11] [12] . ESCRT-III components have been proposed to mediate midbody abscission through their constriction of midbody membranes 10, 11, 12, 30, 31 . The interaction of the centrosomal protein TTC19 with the ESCRT-III subunit CHMP4B uncovers an interplay between this regulator of late cytokinesis and the ESCRT machinery. We propose that TTC19, through its direct interaction with FYVE-CENT and CHMP4B, could regulate the function of ESCRT-III components at the midbody, possibly by controlling the oligomerization of CHMP4B, and could in this way control the abscission process.
It was recently shown that the ZFYVE26 gene encoding FYVE-CENT is mutated in patients with hereditary spastic paraplegia 24 . Spastin, a protein that is often found mutated in patients with hereditary spastic paraplegia, has also been shown to localize to the midbody and to control cytokinesis 32, 33 . This raises the possibility that there could be a correlation between aberrant cytokinesis and the aetiology of some forms of hereditary spastic paraplegia.
Three subunits of the PI(3)K-III complex, namely Beclin 1, Bif-1 (BAX-interacting factor 1) and UVRAG (UV radiation resistance associated), have previously been identified as tumour suppressors [34] [35] [36] . Their tumour suppressor activities have been attributed to their involvement in autophagy, a catabolic process that is thought to promote genome stability by scavenging damaged organelles 37 . Our present data suggest an additional potential mechanism for the tumour suppressor function of the PI(3)K-III complex. Failure to complete cytokinesis has been suggested to promote tumorigenesis 5 , and it is interesting to note that the ZFYVE26 gene encoding FYVE-CENT has been found mutated in breast cancer samples with a frequency of more than 10% (ref. 38) . Taken together, our findings reveal a regulatory role for the PI(3)K-III complex and its catalytic product, and it will be interesting to investigate whether this is relevant to carcinogenesis. 
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METHODS
Cell culture and transfections. Media and reagents for cell culture were purchased from Gibco. HeLa, Hep2 and MCF7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS), 5 U ml −1 penicillin and 50 µg ml −1 streptomycin. Cells were transfected with the above expression plasmids using the FUGENE-6 reagent (Roche Molecular Biochemicals) as described by the manufacturer.
Confocal fluorescence microscopy.
Immunofluorescence microscopy was performed with HeLa, Hep2 and MCF7 cells ( data not shown) grown on coverslips. The cells were transfected or not and thereafter were fixed with methanol at -20o C for 10 minutes. After fixation, they were washed with PBS and blocked in RT for 15 minutes with 50 mM NH4Cl in PBS. Finally, the fixed cells were stained with the antibodies indicated, diluted in the blocking buffer. In some experiments, the cells were fixed with 3% paraformaldehyde and thereafter permeabilized with PEM buffer (pH 6.8, 80 mM PIPES, 5mM EGTA, 1 mM MgCl2x6H2O) containing 0.05 % saponin buffer for 5 minutes. The fixed cells were washed with PBS and blocked with 50 mM NH4Cl in PBS. Finally, the fixed cells were stained with the antibodies indicated, diluted in PBS containing 0,05% saponin. Liposome binding assay. Biotin-labelled PolyPIPosomes from Echelon Biosciences were incubated with GST-tagged protein of interest and reaction buffer (1 mM dithiothreitol (DTT), 2% protease inhibitor cocktail, 0.1% BSA, 10 µM ZnCl 2 in 30 mM Tris-HCl / 150 mM NaCl buffer) for 1 h with rotation at 4 °C. Thereafter, streptavidin beads from Dynabeads (Dynal, Invitrogen) were washed three times with reaction buffer and were added to the reaction and incubated further for 1 h, rotated at 4 °C. The samples were washed three times in buffer in a magnetic rack, all buffer was removed and SDS-PAGE sample buffer was added. The samples were boiled for 10 min and analysed by 4-20% gradient SDS-PAGE and immunoblotting using anti-GST horseradish peroxidase (HRP)-conjugated antibody.
Immunoblotting. To determine the cell-specific distribution of FYVE-CENT, various cell lines were lysed in lysis buffer (25 mM HEPES pH 7.2, 125 mM potassium acetate, 2.5 mM magnesium acetate, 5 mM EGTA, 1 mM DTT, 0.5% Nonidet P40, 1:100 proteinase inhibitor mix (Roche Applied Science)). After centrifugation for 5 min at 5,000g the samples were sonicated for 10 s at 70 volts and 30 µg of protein of the whole lysate was subjected to SDS-PAGE (4-20% gradient) and transferred to Immobilon-P membrane (Millipore) for immunoblotting. The blot was developed with the Supersignal West Pico Chemiluminescent substrate kit or Supersignal West Dura Extended Duration Substrate kit (Pierce).
GST pull-down assay. The GST-FYVE-CENT C terminus (residues 2120-2539), the GST-FYVE-CENT C terminus (1807-2539) and the mutant R1945Q constructs as well as the GST-CHMP4B constructs were expressed by transforming BL21 cells. The protein expression was induced with 0.3 mM isopropyl β-d-thiogalactoside for 3 h at 37 °C. The bacteria pellet was resuspended in lysis buffer (0.1 M NaCl, 10 mM Na 2 HPO 4 , 1% Triton X-100, 1 mM EDTA, pH 7.4) plus 1 mM DTT and 1:25 proteinase inhibitor mix and sonicated for seven pulses (1 min sonication at 70 V and 1 min on ice). Bacterial lysate or purified GST protein were incubated with glutathione-Sepharose beads (GE Healthcare) for 1 h at room temperature. The beads were washed with lysis buffer (25 mM HEPES pH 7.2, 125 mM potassium acetate, 2.5 mM magnesium acetate, 5 mM EGTA, 1 mM DTT), and then rotated for 1 h at 4 °C with cell lysate from HeLa cells transiently expressing Myc-tagged KIF13A or Myc-tagged TTC19. Finally, the beads were washed three times with lysis buffer and analysed by SDS-PAGE and immunoblotting with anti-Myc antibody.
Co-immunoprecipitation analysis. HeLa cells in 10-cm culture dishes were lysed in ice-cold lysis buffer (20 mM HEPES pH 7.2, 2 mM MgCl 2 , 100 mM NaCl, 0.1 mM EDTA, 0.1% Triton X-100) containing inhibitors (N-ethylmaleimide, mammalian protease inhibitor mixture, phosphatase inhibitor cocktail I and II (Sigma-Aldrich)). The lysates were placed on ice and sonicated before being added to Protein A-coupled magnetic beads (Dynal, Invitrogen) which had been precoupled with mouse antibody against TTC19 in PBS Tween 20. Antibodycoupled magnetic beads and cell lysates were gently mixed for 1 h at 4 °C. The beads were then washed with lysis buffer, eluted in 2 × sample buffer at 95 °C for 5 min. The eluted proteins were subsequently subjected to SDS-PAGE and immunoblotting as described previously.
Antibodies and fluorescent probes. Two peptides corresponding to residues 132-145 (VGHVPDGNPRRESW) and 2300-2313 (KIYLQETSRSSGRK) of FYVE-CENT were synthesized and used for immunization of two rabbits to raise antisera (BioGenes GmbH). A BLAST search of the human genome showed that these peptides are unique to FYVE-CENT. CHMP4B antibody was also synthesized in the same way. Both sera were affinity purified on peptide-containing columns generated with the SulfoLink immobilization kit (Pierce) as described by the manufacturer. Mouse monoclonal antibody against the c-Myc epitope was from the 9E10 hybridoma 39 . Rabbit monoclonal antibody against the c-Myc epitope and goat anti-human KIF13A antibody were purchased from Santa Cruz Biotechnology, Inc. Human anti-EEA1 serum was a gift from B.-H. Toh (Monash University, Melbourne, Australia). Mouse anti-human CD63 antibody was from Developmental Studies Hybridoma Bank (The University of Iowa). Mouse anti-human γ-tubulin and mouse anti-human α-tubulin antibodies were from Sigma-Aldrich. Rabbit anti-mouse TTC19 antibody, rabbit anti-human Aurora B antibody and goat polyclonal anti-GST HRP antibody were purchased from Abcam. Rabbit anti-human VPS34 (PIK3CIII) antibody and rabbit antihuman Beclin 1 antibody were purchased from Cell Signaling Technology. Mouse anti-human CEP55 antibody was purchased from Abnova. Mouse anti-human transferrin receptor antibody was purchased from Zymed Laboratories Inc. HRP-labelled goat anti-rabbit antibody, Cy3-labelled goat anti-rabbit antibody and Cy2-labelled goat anti-mouse antibody were all purchased from Jackson Immunoresearch. A fusion between GST and a tandem FYVE domain from hepatocyte growth factor regulated tyrosine kinase substrate (Hrs) (GST-2×FYVE) as well as a GFP fusion (GFP-2×FYVE) were purified as described previously 21 .
Plasmid constructs. An expression plasmid encoding Myc-epitope-tagged mouse KIF13A was provided by Nobutaka Hirokawa 25 . The Myc-DDK-tagged open reading frame (ORF) clone of Homo sapiens TTC19 (NM_017775.2) was obtained from OriGene Technologies, Inc. All the FYVE-CENT constructs indicated were generated by PCR with the cDNA (ORF) that codes for the protein (NM_015346.2), which was cloned in a pCMV6-XL4 vector by OriGene Technologies, Inc., as template. Synthetic oligonucleotides were from MWG Biotech. The GFP-tagged ORF clone of Homo sapiens FYVE-CENT (NM_015346.2) was obtained from Origene Technologies, Inc. The FYVE-CENT R1835A mutant as well as the FYVE-CENT R1945Q mutant were prepared by PCR mutagenesis. PCR errors were excluded by sequencing. For expression in mammalian cells with Fugene (Roche) transfection, FYVE-CENT constructs were cloned in-frame behind the Myc epitope of a modified pcDNA3 vector 40 . For expression as GST fusion in Escherichia coli BL21 (DE3) cells, the FYVE domain (residues 1807-1870), the FYVE domain with mutation (R1835A) of FYVE-CENT and the C-terminal part (2120-2539) as well as (1807-2539) and with mutation (R1945Q) of FYVE-CENT were cloned into pGEX-6P-3 (Pharmacia Amersham). Expression and purification were performed as described 26 . (siRNA 1: cat. no. J-010552-05, siRNA 2: cat. no. J-010552-06) were purchased from Dharmacon Research as well as two single deconvoluted siRNAs against CHMP4B (siRNA 1: cat. no. J-018075-09). siRNA oligos against KIF13A (siRNA pool and three single deconvoluted siRNAs) were purchased from Santa Cruz Biotechnology, Inc. (pool: cat. no. sc-43380, siRNA1: cat. no. sc-43380 A, siRNA2: cat. no. sc-43380 B, siRNA 3: cat. no. sc-43380 C). The siRNA experiments were performed on HeLa cells that were plated on coverslips in 5-cm dishes 16 h before transfection in DMEM without penicillin and streptomycin. The next day, they were transfected with a mixture of Oligofectamine (Invitrogen) and control RNA duplex or siRNA against FYVE-CENT, VPS34, KIF13A, TTC19 or Beclin 1 in DMEM without serum, penicillin or streptomycin, with a final siRNA concentration of 0.1 µΜ. At 4 h after transfection, reagents were added to a final concentration of 10% FCS, 5 U ml −1 penicillin and 50 µg ml −1 streptomycin. At 3 or 5 days after transfection, the cells were washed with PBS and those in the coverslips were used for immunofluorescence analysis, whereas those on the plate were lysed in lysis buffer and used for immunoblotting analysis. Quantifications showed a good correlation between the extent of knockdown and the biological readout (not shown).
RNA interference
Electron microscopy. For cryoimmunolabelling, HeLa cells were fixed in 4% formaldehyde and 0.2% glutaraldehyde in 0.1 M phosphate buffer pH 7.4, washed, scraped and pelleted in 12% gelatin at 10,000 r.p.m. The samples were infiltrated with 2.3 M sucrose, mounted on sample stubs, and frozen in liquid nitrogen. Sectioning was done on a cryomicrotome (FCS; Leica). Sections were collected with a 1:1 mixture of 2% methylcellulose and 2.3 M sucrose, transferred to Formvar/carboncoated grids, and labelled with the primary antibodies described in immunofluorescence labelling and confocal microscopy, followed by Protein A-gold conjugate. Specimens were observed in a JEM-1230 (JEOL) operating at 80 kV. Micrographs were recorded with a digital camera (Morada; Olympus) using ITEM software (Olympus).
Drosophila methods. To generate cell clones mutant for vps34 in the follicular epithelium, third-instar larvae of the following genotype were heat-shocked for 2 h at 37°C: hsFLP; FRT42D vps34 , GFP-tagged FYVE-CENT construct, Myc-tagged Beclin 1 construct, Myc-tagged KIF13A construct and Myc-tagged TTC19 construct. The cells were washed in PBS and were then processed for confocal microscopy using anti-Myc and Aurora-B antibodies. The experiment was repeated three times, and in total 250-400 cells were analysed. The results were analysed by quantification.
Yeast two-hybrid screening. The yeast two-hybrid screening was based on the C terminus (residues 2120-2539) of FYVE-CENT as bait and performed by Hybrigenics S.A Services using a human breast cancer cell library.
High-content analysis of cytokinesis arrest. siRNA-treated cells were fixed and stained for α-tubulin, Aurora B and DNA (Hoechst). Images were taken with the Olympus Scan R high-content automated fluorescence microscope and an UPLS-APO 40× objective. Typically, 100 pictures were stitched together from each coverslip, and between two and four coverslips were analysed per experiment. The Olympus Scan R analysis software was used to identify and count the number of cells, on the basis of the detection of nuclei stained with Hoechst. The size, total and mean intensity of the nuclei were calculated by the software. By displaying mean intensity of Hoechst over total intensity of Hoechst, scatter plots were generated that showed populations of cells in different stages of the cell cycle. The most easily identified populations were G1 cells, G2 cells and M-phase cells. The M-phase cells were gated and every M-phase gated cell (showing condensed chromatin) was boxed by the software. The images were then analysed manually. The number of cells in cytokinesis was counted on the basis of profiles showing two daughter cells with an apparent midbody stained by Aurora B. The M-phase gating was used as a guide to separate the profiles into two categories: late cytokinesis arrest (with daughter cells having G1-phase nuclei) and early cytokinesis arrest (with daughter cells having M-phase nuclei with condensed chromatin). Prophase and metaphase cells were not counted in this analysis. Centrosomal localisation of FYVE-CENT is mainly mediated by its C-terminus upstream of the FYVE domain, and the C-terminus of FYVE-CENT, including the FYVE domain, mediates its targeting to the midbody a-g, Myc-epitope-tagged deletion constructs of FYVE-CENT were expressed as indicated. HeLa cells were transfected with these constructs and stained for Myc (red) and γ-Tubulin (green). The very C-terminal part of FYVE-CENT (residues 2120-2539) has the most prominent centrosomal staining (f), but also the N-terminus localises weakly to the centrosome (arrowsin a). Mutation in the FYVE domain (R1835A) shown in (g) is not responsible for centrosomal localisation. h-m, Myc-epitope-tagged deletion constructs of FYVE-CENT were expressed as indicated. Hela cells were transfected with these constructs and stained for myc (green) and γ-Tubulin (green). The construct containing the FYVE domain (residues 1807-2120) has the most prominent midbody staining (l). Also the N-terminal part (residues 1-360) localises to the midbody, albeit to a lower extent (h). Scale bars, 5 μm. Figure S12 CHMP4B interacts with TTC19 and controls accumulation of TTC19 at the midbody. a-b, Confocal micrographs of HeLa cells stained with anti-CHMP4B antibody and the midbody marker Aurora B. CHMP4B localises to the midbody (arrows). c-d, HeLa cells transiently overexpressing myc-TTC19 were pulled down with recombinant GST-CHMP4B fusion protein or GST protein immobilized on glutathione-Sepharose beads. The beads were analyzed by SDS-PAGE and immunoblotting using anti-myc antibody (c). The amount of GST-CHMP4B fusion protein and GST protein used in the pull-down experiment are visualized by Ponceau S staining (d). e, CHMP4B was immunoprecipitated from a HeLa cell lysate, and the Western blot of the lysate (2 %) and immunoprecipitate was probed with antibodies against TTC19 (upper) and CHMP4B (lower). Note that the blot shows the lower-migrating (42-kDa) form of TTC19 as the higher (55-kDa) form was masked by immunoglobulin heavy chain. f, Western blot analysis demonstrating efficient reduction of protein levels of CHMP4B after siRNA knock down. g-h, Confocal micrographs of cells stained with Aurora B and anti-TTC19 after treatment with siRNA against CHMP4B. In cells depleted for CHMP4B there is a significant decrease of TTC19 at the midbody. i, Graphic presentation of quantification of results shown in g, h . Scale bars, a, b: 5 μm, g, h: 1 μm. 
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